Filtered By:
Education: Study
Management: Funding
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 349 results found since Jan 2013.
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Publication date: Available online 29 January 2018 Source:The Lancet Haematology Author(s): Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Helle Toldbod, Lone Bredo Pedersen, Carsten Utoft Niemann, Christina Dahl, Hanne Kuitunen, Christian H Geisler, Kirsten Grønbæk, Arne Kolstad Background Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published ...
Source: The Lancet Haematology - January 30, 2018 Category: Hematology Source Type: research
Mitralign raises $10m
Mitralign, which is looking to commercialize its namesake mitral valve treatment and pursue regulatory nods for its Trialign tricuspid valve device, said it raised nearly $10 million.
The $9.8 million funding, of a hoped-for $30.2 million, came from 19 unnamed investors beginning last September, the Tewksbury, Mass.-based company said in a regulatory filing. Mitralign raised a $40 million Series E round in May 2016.
The Mitralign and Trialign devices are designed to use wire and catheters to implant polyester anchors within the annulus of the mitral and tricuspid valves. The anchors are then cinched together to reduce v...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Replacement Heart Valves Wall Street Beat Mitralign Inc. Source Type: news
IDx Closer to Nod for Diabetic Retinopathy Diagnostic
Privately held IDx is developing an artificial intelligence-based system that could help with the diagnosis diabetic retinopathy – a disease that leads to blindness if undetected.
The company met its endpoints in a pivotal trial of the IDx-DR system. The trial involved 900 diabetes patients at 10 sites. The study was designed to evaluate the diagnostic accuracy of the technology in detecting moderate to severe diabetic retinopathy, including macular edema.
The results of the pivotal trial met the study hypotheses that were developed in consultation with FDA and demonstrated the IDx-DR system exceeded these performance go...
Source: MDDI - February 23, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Medical Device Business Source Type: news
Effectiveness of a community-based educational programme in reducing the cumulative incidence and prevalence of human Taenia solium cysticercosis in Burkina Faso in 2011 –14 (EFECAB): a cluster-randomised controlled trial
This study is registered with ClinicalTrials.gov, number NCT0309339. Findings Two villages in the same randomisation block were excluded, resulting in a final sample size of 58 villages. Overall, the intervention tended towards a decrease in the cumulative incidence of active cysticercosis from baseline to after randomisation (adjusted cumulative incidence ratio 0·65, 95% Bayesian credible interval [95% CrI] 0·39–1·05) and a decrease in active cysticercosis prevalence from baseline to after randomisation (adjusted prevalence proportion ratio 0·84; 95% CrI 0·59–1·18). The intervention was shown to be effective in ...
Source: The Lancet Global Health - March 10, 2018 Category: International Medicine & Public Health Source Type: research
Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study
Publication date: Available online 9 April 2018 Source:The Lancet Respiratory Medicine Author(s): Gregor Warnecke, Dirk Van Raemdonck, Michael A Smith, Gilbert Massard, Jasleen Kukreja, Federico Rea, Gabriel Loor, Fabio De Robertis, Jayan Nagendran, Kumud K Dhital, Francisco Javier Moradiellos Díez, Christoph Knosalla, Christian A Bermudez, Steven Tsui, Kenneth McCurry, I-Wen Wang, Tobias Deuse, Guy Lesèche, Pascal Thomas, Igor Tudorache, Christian Kühn, Murat Avsar, Bettina Wiegmann, Wiebke Sommer, Arne Neyrinck, Marco Schiavon, Fiorella Calebrese, Nichola Santelmo, Anne Olland, Pierre-Emanuel Falcoz, Andre R Simon, A...
Source: The Lancet Respiratory Medicine - April 10, 2018 Category: Respiratory Medicine Source Type: research
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Publication date: Available online 11 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Bryan Williams, Thomas M MacDonald, Steve V Morant, David J Webb, Peter Sever, Gordon T McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Sandosh Padmanabhan, Isla S Mackenzie, Jackie Salsbury, Morris J Brown Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. Methods PATHWA...
Source: The Lancet Diabetes and Endocrinology - April 12, 2018 Category: Endocrinology Source Type: research
Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies
Publication date: 14–20 April 2018 Source:The Lancet, Volume 391, Issue 10129 Author(s): Angela M Wood, Stephen Kaptoge, Adam S Butterworth, Peter Willeit, Samantha Warnakula, Thomas Bolton, Ellie Paige, Dirk S Paul, Michael Sweeting, Stephen Burgess, Steven Bell, William Astle, David Stevens, Albert Koulman, Randi M Selmer, W M Monique Verschuren, Shinichi Sato, Inger Njølstad, Mark Woodward, Veikko Salomaa, Børge G Nordestgaard, Bu B Yeap, Astrid Fletcher, Olle Melander, Lewis H Kuller, Beverley Balkau, Michael Marmot, Wolfgang Koenig, Edoardo Casiglia, Cyrus Cooper, Volker Arndt, Oscar H Franco, Patrik Wennberg, Jo...
Source: The Lancet - April 13, 2018 Category: General Medicine Source Type: research
Emboline raises $10m Series B for TAVR embolism filter
Emboline said today that it pulled in a $10 million Series B round for the namesake embolic protector it’s developing for heart valve replacement procedures.
The Emboliner catheter is designed to prevent blood clots from passing into the cerebral vasculature during transcatheter aortic valve replacements. Santa Cruz, Calif.-based Emboline said the round includes $3 million from a consortium led by SV Tech Ventures and Shangbay Capital and $7 million in already-issued convertible notes. The cash is earmarked for Emboline’s SafePass clinical trial, submission for CE Mark approval and initial commercialization, ...
Source: Mass Device - April 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Replacement Heart Valves Vascular Wall Street Beat Emboline Source Type: news
Getting in on the Embolic Protection Action for TAVR
There has been an increase in the need for embolization protection devices as the risk for stroke and other neurological damage from transcatheter aortic valve replacement (TAVR) procedures continues to become more prevalent.
Santa Cruz, CA -based Emboline is looking to enter the embolization protection space, which is set to grow from $406 million this year to $605 million by 2023, according to a report from ResearchandMarkets. The emerging medtech company's contribution to the space would come from its Emboliner Embolic Protection Catheter.
The Emboliner is a cylindrical mesh filter that completely lines the aorta...
Source: MDDI - April 20, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Cardiovascular Source Type: news
Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis
This study is registered with PROSPERO, number CRD42017065697. Findings 25 randomised controlled trials enrolled 16 037 patients with sepsis, critical illness, stroke, trauma, myocardial infarction, or cardiac arrest, and patients who had emergency surgery. Compared with a conservative oxygen strategy, a liberal oxygen strategy (median baseline saturation of peripheral oxygen [SpO2] across trials, 96% [range 94–99%, IQR 96–98]) increased mortality in-hospital (relative risk [RR] 1·21, 95% CI 1·03–1·43, I 2=0%, high quality), at 30 days (RR 1·14, 95% CI 1·01–1·29, I 2=0%, high quality), and at longest follow...
Source: The Lancet - April 28, 2018 Category: General Medicine Source Type: research
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study
Publication date: Available online 30 April 2018 Source:The Lancet Neurology Author(s): Cyril Pottier, Xiaolai Zhou, Ralph B Perkerson, Matt Baker, Gregory D Jenkins, Daniel J Serie, Roberta Ghidoni, Luisa Benussi, Giuliano Binetti, Adolfo López de Munain, Miren Zulaica, Fermin Moreno, Isabelle Le Ber, Florence Pasquier, Didier Hannequin, Raquel Sánchez-Valle, Anna Antonell, Albert Lladó, Tammee M Parsons, NiCole A Finch, Elizabeth C Finger, Carol F Lippa, Edward D Huey, Manuela Neumann, Peter Heutink, Matthis Synofzik, Carlo Wilke, Robert A Rissman, Jaroslaw Slawek, Emilia Sitek, Peter Johannsen, Jørgen E Nielsen, Yi...
Source: The Lancet Neurology - May 1, 2018 Category: Neurology Source Type: research
Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies
Publication date: Available online 8 May 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Prospective Studies Collaboration and Asia Pacific Cohort Studies CollaborationLGnatiucWGHerringtonJHalseyJTuomilehtoXFangHCKimDDe BacquerAJDobsonMHCriquiDRJacobsJrDALeonSAEPetersHUeshimaPSherlikerRPetoRCollinsRRHuxleyJREmbersonMWoodwardSLewingtonNAokiHArimaEArnesenAAromaaGAssmannDLBachmanCBaigentHBartholomewABenetosCBengtssonDBennettCBjörkelundHBlackburnKBonaaEBoyleRBroadhurstJCarstensenLChamblessZChenSKChewRClarkeCCoxJDCurbRD'AgostinoCDateGDavey SmithGDe BackerSSDhaliwalXFDuanPDucimetiereSDuffyHEliassenPElwoodJEm...
Source: The Lancet Diabetes and Endocrinology - May 9, 2018 Category: Endocrinology Source Type: research
Work stress and risk of death in men and women with and without cardiometabolic disease: a multicohort study
Publication date: Available online 5 June 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Mika Kivimäki, Jaana Pentti, Jane E Ferrie, G David Batty, Solja T Nyberg, Markus Jokela, Marianna Virtanen, Lars Alfredsson, Nico Dragano, Eleonor I Fransson, Marcel Goldberg, Anders Knutsson, Markku Koskenvuo, Aki Koskinen, Anne Kouvonen, Ritva Luukkonen, Tuula Oksanen, Reiner Rugulies, Johannes Siegrist, Archana Singh-Manoux, Sakari Suominen, Töres Theorell, Ari Väänänen, Jussi Vahtera, Peter J M Westerholm, Hugo Westerlund, Marie Zins, Timo Strandberg, Andrew Steptoe, John Deanfield Background Although som...
Source: The Lancet Diabetes and Endocrinology - June 6, 2018 Category: Endocrinology Source Type: research
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial
Publication date: 9–15 June 2018 Source:The Lancet, Volume 391, Issue 10137 Author(s): P J Devereaux, Emmanuelle Duceppe, Gordon Guyatt, Vikas Tandon, Reitze Rodseth, Bruce M Biccard, Denis Xavier, Wojciech Szczeklik, Christian S Meyhoff, Jessica Vincent, Maria Grazia Franzosi, Sadeesh K Srinathan, Jason Erb, Patrick Magloire, John Neary, Mangala Rao, Prashant V Rahate, Navneet K Chaudhry, Bongani Mayosi, Miriam de Nadal, Pilar Paniagua Iglesias, Otavio Berwanger, Juan Carlos Villar, Fernando Botto, John W Eikelboom, Daniel I Sessler, Clive Kearon, Shirley Pettit, Mukul Sharma, Stuart J Connolly, Shrikant I Bangdiwala, ...
Source: The Lancet - June 8, 2018 Category: General Medicine Source Type: research
Air pollution may be linked to heightened dementia risk
Study tracked exposure to air and noise pollution Related items fromOnMedica UK death rate spikes for first time in a decade Dementia leading cause of death in women over 80 Risk of Alzheimer ’s lower in people with gout Dementia and stroke funding remains too low, say experts Dementia risk rises for middle-age abstainers and heavy drinkers
Source: OnMedica Latest News - September 19, 2018 Category: UK Health Source Type: news
